Literature DB >> 22833834

A time to test, a time to treat.

Andrew J Weickhardt1, Robert C Doebele, D Ross Camidge.   

Abstract

Year:  2012        PMID： 22833834      PMCID： PMC3378225          DOI： 10.3978/j.issn.2072-1439.2012.03.13

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  24 in total

1.  EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry.

Authors:  Lynette M Sholl; Yun Xiao; Victoria Joshi; Beow Y Yeap; Leigh-Anne Cioffredi; David M Jackman; Charles Lee; Pasi A Jänne; Neal I Lindeman
Journal:  Am J Clin Pathol       Date:  2010-06       Impact factor: 2.493

2.  Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

Authors:  J Baselga; D Rischin; M Ranson; H Calvert; E Raymond; D G Kieback; S B Kaye; L Gianni; A Harris; T Bjork; S D Averbuch; A Feyereislova; H Swaisland; F Rojo; J Albanell
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

3.  Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

Authors:  Fred R Hirsch; Marileila Varella-Garcia; Jason McCoy; Howard West; Ana Carolina Xavier; Paul Gumerlock; Paul A Bunn; Wilbur A Franklin; John Crowley; David R Gandara
Journal:  J Clin Oncol       Date:  2005-07-05       Impact factor: 44.544

4.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

Review 5.  Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

Authors:  William Pao; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

6.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

7.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

8.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

9.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

10.  Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.

Authors:  J D Sato; T Kawamoto; A D Le; J Mendelsohn; J Polikoff; G H Sato
Journal:  Mol Biol Med       Date:  1983-12
View more
  1 in total

1.  Translating Hispanic Genomic Factors in Lung Cancer Into Clinical Practice: EGFR Testing for Improved Outcomes.

Authors:  Janella Hudson; Teresita Munoz-Antonia; Eric Haura; Doug Cress; Vani N Simmons; Gwendolyn P Quinn
Journal:  Gene Cell Tissue       Date:  2016-02-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.